Advances in Lymphoma
Transcript: Using PET to guide cHL treatment de-escalation
Dr Francine Foss
All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
I think we're all very concerned about the long-term toxicities of combined modality therapy and Hodgkin's disease, especially since we cure many of these patients. Many of these patients are young when they present, so we're looking at 30, 40, even 50 years of survival for these patients. I think it's critical in that setting to try to reduce toxicity and especially long-term risk, and that's where these regimens have really, I think, contributed significantly to the field. And so what these prospective and retrospective analyses have demonstrated is that, in fact, you can eliminate toxic drugs like bleomycin for sure.
You can also shorten up chemotherapy, and you can use PET scanning as a modality to determine which patients need further therapy, be it further chemotherapy or involved field radiotherapy. And I think the other important aspect is questioning the role of involved field radiotherapy as well in those patients that achieve an early PET negative status. So I think these studies are gonna be critically important moving forward. I think the average practising physician needs to make these decisions, and evidence basis is really how we do that. So given these two studies, I think that the field is gonna shift toward less therapy for these early staged patients rather than more.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event